Politics and Government Politics and Government
Wed, December 11, 2024

Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump


Published on 2024-12-11 10:20:36 - MSN
  Print publication without navigation

  • Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.

The article from MSN discusses comments made by David Ricks, the CEO of Eli Lilly, regarding the pharmaceutical industry's priorities under a potential second term of former President Donald Trump. Ricks highlighted that the industry is focused on tax and regulation reform, as well as addressing drug affordability. He noted that while Trump's previous administration had been supportive of the industry through tax cuts and deregulation, there were also pressures to lower drug prices. Ricks expressed hope for a balanced approach that would encourage innovation while making medications more accessible and affordable to patients. He also mentioned the importance of maintaining a dialogue with policymakers to ensure that any reforms would not stifle the development of new treatments.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/politics/government/lilly-ceo-says-tax-and-regulation-reform-drug-affordability-are-focuses-under-trump/ar-AA1vCOZf ]
Contributing Sources